BPG is committed to discovery and dissemination of knowledge
Featured Articles
5/7/2021 12:36:57 PM | Browse: 1211 | Download: 1973
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 62648
Country Japan
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Molecular-targeted therapy toward precision medicine for gastrointestinal cancer: Current progress and challenges
Manuscript Source Invited Manuscript
All Author List Tasuku Matsuoka and Masakazu Yashiro
Funding Agency and Grant Number
Funding Agency Grant Number
KAKENHI (Grant-in-Aid for Scientific Research) 18H02883
Corresponding Author Masakazu Yashiro, MD, PhD, Associate Professor, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. m9312510@med.osaka-cu.ac.jp
Key Words Gastrointestinal cancer; Esophageal cancer; Gastric cancer; Colorectal cancer; Targeted therapy; Precision medicine
Core Tip Outcomes in metastatic gastrointestinal (GI) cancer are improving with the better understanding and use of targeted therapies. Herein, a review of the literature and recent conference presentations was conducted regarding the topic of targeted therapies for precision medicine in GI cancer. This article clarifies the current evidence for targeted therapies in GI cancer by evaluating the latest data regarding anti- epidermal growth factor receptor, human epidermal growth factor receptor 2, vascular endothelial growth factor, phosphatidylinositol-3-hydroxykinase/protein kinase B, tumor growth factor-β, mesenchymal-epithelial transition, wireless network technology, poly (ADP-ribose) polymerase, and immunotherapies.
Publish Date 2021-05-07 09:15
Citation Matsuoka T, Yashiro M. Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges. World J Gastrointest Oncol 2021; 13(5): 366-390
URL https://www.wjgnet.com/1948-5204/full/v13/i5/366.htm
DOI https://dx.doi.org/10.4251/wjgo.v13.i5.366
Full Article (PDF) WJGO-13-366.pdf
Full Article (Word) WJGO-13-366.docx